ATI RN
Nursing Cardiovascular Drug List Quizlet Questions
Question 1 of 5
The systemic effects of hexamethonium include all of the following EXCEPT:
Correct Answer: D
Rationale: The correct answer is D because hexamethonium is a ganglionic blocker that inhibits the sympathetic nervous system, leading to reduced peripheral vascular resistance and venous return (Choice A), partial mydriasis and loss of accommodation (Choice B), and constipation and urinary retention (Choice C). Stimulation of thermoregulatory sweating is not a systemic effect of hexamethonium, making Choice D incorrect. Hexamethonium does not affect the thermoregulatory sweating mechanism in the body.
Question 2 of 5
Indicate adrenoreceptor antagonist agents which are used for the management of pheochromocytoma:
Correct Answer: D
Rationale: The correct answer is D: Αlfa-receptor antagonists. Alpha-receptor antagonists, such as phenoxybenzamine and phentolamine, are used in the management of pheochromocytoma to block the effects of excess catecholamines released by the tumor. These agents help control hypertension and other symptoms associated with pheochromocytoma. A: Selective beta2-receptor antagonists are not typically used in the management of pheochromocytoma because they do not target the alpha-receptors responsible for the symptoms. B: Nonselective beta-receptor antagonists may be used as adjunct therapy in pheochromocytoma to control tachycardia, but they do not directly address the alpha-receptor effects. C: Indirect-acting adrenoreceptor antagonist drugs do not specifically target the alpha-receptors involved in pheochromocytoma symptoms. In summary,
Question 3 of 5
Indicate the mechanism of barbiturate action (at hypnotic doses):
Correct Answer: D
Rationale: The correct answer is D because barbiturates act by increasing the duration, frequency, and direct activation of GABA-gated Cl- channels. This leads to hyperpolarization of neurons, resulting in sedative and hypnotic effects. Choice A is correct as barbiturates prolong the opening of Cl- channels. Choice B is incorrect as barbiturates enhance, not directly activate, the Cl- channels. Choice C is incorrect as barbiturates increase the duration, not frequency, of Cl- channel opening events. Therefore, the correct answer is D as it encompasses all the mechanisms of barbiturate action.
Question 4 of 5
The mechanism of vigabatrin′s action is:
Correct Answer: B
Rationale: The correct answer is B: Inhibition of GABA aminotransferase. Vigabatrin increases GABA levels by inhibiting GABA aminotransferase enzyme, which is responsible for GABA breakdown. This leads to enhanced GABAergic inhibition in the brain. A: Direct action on the GABA receptor-chloride channel complex is incorrect as vigabatrin does not directly bind to GABA receptors. C: NMDA receptor blockade via the glycine binding site is incorrect as vigabatrin does not affect NMDA receptors. D: Inhibition of GABA neuronal reuptake from synapses is incorrect as vigabatrin does not affect GABA reuptake mechanisms.
Question 5 of 5
Indicate selective catechol-O-methyltransferase inhibitor which prolongs the action of levodopa by diminishing its peripheral metabolism:
Correct Answer: C
Rationale: Rationale: 1. Tolcapone inhibits catechol-O-methyltransferase (COMT), reducing levodopa peripheral metabolism. 2. By prolonging levodopa's action, it enhances its efficacy in treating Parkinson's disease. 3. Carbidopa enhances levodopa bioavailability, not directly affecting its peripheral metabolism. 4. Clozapine is an antipsychotic with no COMT inhibitory activity. 5. Rasagiline is a monoamine oxidase-B inhibitor, not a COMT inhibitor.